Vor Biopharma
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Vor Biopharma sits in the upper quartile of US sponsors by registered trial count (#2,085 of 15,742 sponsors by registered trial count).
Vor Biopharma: 6 sponsored US clinical trials, 2 recruiting.
Vor Biopharma sponsors 6 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Sjogren's Disease, with 1 trials.
Upper-quartile sponsor footprint
Vor Biopharma sits in the upper quartile of the sponsor corpus (#2,085 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
6 total, page 1 of 1
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
NCT07404865
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
NCT06456580
Donor-Derived Anti-CD33 CAR T Cell Therapy (VCAR33) in Patients With Relapsed or Refractory AML After Allogeneic Hematopoietic Cell Transplant
NCT05984199
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)
NCT05306574
A Long-term Follow-up Study of Patients Who Received VOR33
NCT05309733
Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS
NCT04849910
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 3 | 3 |
Therapeutic Areas
What is open in the Vor Biopharma pipeline
2 recruiting of 6 indexed (33% open).
Phase mix: 3 late (III/IV) vs 2 early (I/II) (balanced across stages).
Top condition: Primary Sjogren's Disease (1 trial), 1 other listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Vor Biopharma: open-pipeline peers nationwide
Peers matched on 6 registered trials and 33% open enrollment, not the therapeutic-area sidebar.
Vor Biopharma sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 6 trials (± recruiting share)
- 23andMe · 6 trials · 0% recruiting
- Aardvark Therapeutics · 6 trials · 0% recruiting
- Abbisko Therapeutics Co · 6 trials · 67% recruiting
- AbGenomics B.V Taiwan Branch · 6 trials · 0% recruiting
Sponsors near 33% open enrollment (± trial volume)
- Aadi Bioscience · 33% recruiting · 9 trials
- Aaron Cook · 33% recruiting · 3 trials
- Abivax S.A. · 33% recruiting · 6 trials
- Actuated Medical · 33% recruiting · 3 trials
Related
What to do with this Vor Biopharma page
6 registered trials is a research-attention snapshot, not an endorsement of Vor Biopharma or any single study.
- 2 of Vor Biopharma's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Sjogren's Disease is the condition Vor Biopharma studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Sjogren's Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Vor Biopharma pipeline card: 6 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.